Bacterial susceptibility microfluidic chip and method of use thereof
By designing a bacterial drug susceptibility microfluidic chip, utilizing the principles of microchannels and centrifugal force, the problems of aerosol contamination and cumbersome operation in existing technologies have been solved, enabling rapid and accurate drug susceptibility analysis, reducing equipment costs and the risk of mechanical failure, and making it suitable for drug susceptibility testing of various antibiotics and microbial detection under harsh environments.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- JIANG SU LING XIN SHENG WU KE JI YOU XIAN GONG SI
- Filing Date
- 2023-05-25
- Publication Date
- 2026-07-21
AI Technical Summary
Existing technologies for detecting the effectiveness of antibiotics against pathogens suffer from problems such as a high probability of aerosol and cross-contamination, cumbersome operation, and complex and costly equipment, making it difficult to meet the needs of rapid and accurate drug sensitivity analysis.
A bacterial antimicrobial susceptibility microfluidic chip was designed, which integrates dried substrates of antibiotics with different concentration gradients using the principles of microchannels and centrifugal force. The microchannels connect the bacterial solution loading tank, the flow guide channel, and the antimicrobial susceptibility testing chamber, and the chip allows for rapid sample loading using centrifugal force, avoiding aerosol contamination and simplifying the device structure.
It enables rapid and accurate drug sensitivity analysis, reduces amplification culture time and equipment costs, lowers the probability of mechanical failure, ensures the accuracy of results, and is suitable for microbial detection in harsh environments.
Smart Images
Figure CN116673078B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of drug susceptibility testing, specifically to a bacterial drug susceptibility microfluidic chip and its usage method. Background Technology
[0002] Infectious diseases, especially bacterial infections, are one of the leading causes of death in clinical practice, with over 95% of cases due to a lack of timely diagnosis and treatment. However, conventional methods for pathogen identification and drug sensitivity analysis are cumbersome, time-consuming (24-72 hours), and labor-intensive, failing to meet the clinical need for early diagnosis and timely, effective treatment of infectious diseases. While time-of-flight mass spectrometry (TOF-MS) has provided rapid and effective pathogen identification, it is imperative to develop a new, sensitive, and rapid method (platform) for detecting effective antibiotic information in pathogens. For example, Chinese patent CN114958954A discloses a culture medium and interpretation method for Helicobacter pylori drug sensitivity testing. This uniquely formulated culture medium efficiently and stably promotes the growth of Helicobacter pylori, ensuring that the inhibition zone and its size in the drug sensitivity test results are only related to the type and concentration of antibiotic. Therefore, based on the presence and size of the inhibition zone, and according to the established interpretation method and standards, the sensitivity of different Helicobacter pylori isolates to different antibiotics can be scientifically determined. However, it requires adding bacterial solution to the microwells using a pipette. Since the antibiotic drug sensitivity test has a large number of microwells (around 40), the sample addition process is very complicated and inefficient. The complicated sample addition process increases the chance of aerosols and cross-contamination, and there is also a certain amount of sample addition error.
[0003] For example, Chinese patent CN115104030A discloses a method for detecting carbapenem-resistant pathogenic strains in biological samples. This method directly identifies carbapenem-degrading enzymes, particularly KPC, OXA, NDM, IMP, VIM, and / or GES proteins, through mass spectrometry. This allows for rapid determination of whether the pathogenic strain has developed antibiotic resistance and the types of resistance-related proteins. However, the current fully automated microbial identification and antimicrobial susceptibility analyzers used in microplate microsusceptibility testing are complex in structure and large in size due to the complicated sample loading process. This necessitates the provision of an XYZ robotic arm and a microplate cover gripping device.
[0004] The method for detecting whether antibiotics are effective against pathogens usually involves adding bacterial solutions to microwells using a pipette and then performing identification and analysis using a fully automated microbial identification and drug sensitivity analyzer. This method increases the chance of aerosols and cross-contamination during the sample addition process, which can cause errors in the identification results and also increases the complexity of the operation. Summary of the Invention
[0005] To address the problems of existing methods for detecting the effectiveness of antibiotics against pathogens, such as the risk of aerosol and cross-contamination, and the relatively cumbersome operation, this application designs a bacterial drug sensitivity microfluidic chip and its usage method, aiming to increase detection efficiency while avoiding external contamination during the detection process.
[0006] A bacterial antimicrobial susceptibility microfluidic chip, including a microbial identification reagent tray;
[0007] The microbial identification reagent tray is provided with a shaft hole and a bacterial solution dispensing groove;
[0008] The microbial identification reagent tray is equipped with a microchannel, a bacterial liquid guiding channel, and a bacterial drug sensitivity testing chamber.
[0009] The shaft hole is located in the center of the microbial identification reagent tray;
[0010] The bacterial solution loading groove is located on the outside of the shaft hole;
[0011] The bacterial solution guide channel is located between the bacterial solution sample loading tank and the bacterial drug susceptibility testing chamber, and the bacterial drug susceptibility testing chamber is located on the outermost side of the microbial identification reagent tray.
[0012] The bacterial solution sample loading tank, bacterial solution guide channel, and bacterial drug sensitivity testing chamber are connected by a microchannel.
[0013] Preferably, the microbial identification reagent tray is further provided with vent holes, which are connected to the bacterial liquid guide channel through microchannels.
[0014] Preferably, the bacterial susceptibility testing chambers are evenly distributed on the outside of the bacterial solution guide channel and are connected to the bacterial solution guide channel through a microchannel.
[0015] Preferably, the different bacterial susceptibility testing chambers are equipped with dried substrates of different concentration gradients of antibiotics.
[0016] Preferably, the microchannel is an S-shaped microfluidic channel.
[0017] Preferably, the bacterial solution sample loading tank has a semi-circular arc-shaped structure.
[0018] Preferably, the tail end of the bacterial solution sample addition tank is connected to the bacterial solution guide channel via a microchannel.
[0019] Preferably, the bacterial solution addition groove is further provided with a dynamic balancing groove at the position corresponding to the shaft hole.
[0020] A method for using a bacterial antimicrobial susceptibility microfluidic chip includes the following steps:
[0021] Step S1: Add a sample solution of a certain concentration of the bacterial solution to be tested into the bacterial solution sample tank;
[0022] Step S2: Under the action of centrifugal force, the bacterial solution flows through the microchannel to the bacterial solution guide channel, and then fills each bacterial drug sensitivity testing chamber through the microchannel.
[0023] Step S3: Place the microfluidic chip in a bacterial incubator and incubate for a certain period of time, then remove it.
[0024] Step S4: Place the sample into a microfluidic chip detector. The microfluidic chip detector performs photomicrography on each bacterial drug susceptibility testing chamber. By comparing the color or turbidity changes in the photographic images before and after culture, it is determined whether bacteria have grown. Combined with the type and concentration of antibiotics in each bacterial drug susceptibility testing chamber, the final drug susceptibility analysis results are given.
[0025] Preferably, in step S1, for certain microorganisms that require a harsh environment for cultivation, after the bacterial culture is centrifuged and enters the bacterial drug sensitivity testing chamber, chemical reagents are added to the bacterial culture sample tank to react and establish a harsh microenvironment, and the bacterial culture sample tank and the vent are sealed with a membrane.
[0026] The beneficial effects obtained by this invention are as follows:
[0027] 1. The bacterial drug sensitivity microfluidic chip designed in this invention has a small volume of each bacterial drug sensitivity measurement chamber, and the amount of bacterial solution used is also smaller. The reduction of bacterial solution means that the number of bacteria required to prepare a bacterial solution of a certain concentration is reduced. Therefore, this application can greatly reduce the process and time of amplification culture.
[0028] 2. The present invention designs a bacterial drug sensitivity microfluidic chip, in which different bacterial drug sensitivity assay chambers are set with dried substrates of antibiotics at different concentration gradients. One microfluidic chip can integrate several antibiotics, and each antibiotic can be set with several concentration gradients, which can save time and effort to complete multiple antibiotic drug sensitivity MIC tests required in clinical practice at one time.
[0029] 3. The bacterial drug sensitivity microfluidic chip designed in this invention only requires a centrifugation module to replace the previously complex XYZ robotic arm and microporous plate cover gripping device. While simplifying the design, it reduces equipment costs and the probability of mechanical failure.
[0030] 4. The bacterial drug sensitivity microfluidic chip designed in this invention, by designing the microchannel as an S-shaped microfluidic channel, can delay the volatilization of bacterial culture medium and ensure the accuracy of result identification.
[0031] 5. The present invention provides a method for using a bacterial drug sensitivity microfluidic chip, which utilizes the principle of centrifugation to centrifuge the bacterial solution to be tested to fill the bacterial drug sensitivity testing chamber in one go. The sample addition process is quick, simple, and highly efficient. The sample addition process is carried out inside the microfluidic chip, so there is no aerosol generation or cross-contamination.
[0032] 6. For certain microorganisms that require a harsh environment for cultivation, after the bacterial culture is centrifuged and enters the bacterial drug susceptibility testing chamber, chemical reagents can be added to the bacterial culture sample tank to create a harsh microenvironment. The bacterial culture sample tank and the vent holes can be sealed with a membrane. Through the above design, this application can meet the drug susceptibility testing needs of some microorganisms that require a harsh environment for cultivation.
[0033] The above description is only an overview of the technical solution of this application. In order to better understand the technical means of this application and implement it in accordance with the contents of the specification, and to make the above and other objects, features and advantages of this application more obvious and understandable, the preferred embodiments of this application are described in detail below with reference to the accompanying drawings.
[0034] The above and other objects, advantages and features of this application will become more apparent to those skilled in the art from the following detailed description of specific embodiments in conjunction with the accompanying drawings. Attached Figure Description
[0035] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort. In all drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn to scale.
[0036] Figure 1 A plan view of a bacterial antimicrobial susceptibility microfluidic chip provided in this application;
[0037] Figure 2 This application provides a structural diagram of a bacterial antimicrobial susceptibility microfluidic chip.
[0038] Figure labels: 1. Microbial identification reagent tray; 2. Shaft hole; 3. Bacterial solution sample loading groove; 4. Microchannel; 5. Bacterial solution guide channel; 6. Bacterial drug sensitivity test chamber; 7. Vent hole; 8. Dynamic balance groove. Detailed Implementation
[0039] To make the objectives, technical solutions, and advantages of the embodiments of this application clearer, the technical solutions of the embodiments of this application will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this application, not all embodiments. In the following description, specific details such as specific configurations and components are provided merely to help fully understand the embodiments of this application. Therefore, those skilled in the art should understand that various changes and modifications can be made to the embodiments described herein without departing from the scope and spirit of this application. In addition, for clarity and brevity, descriptions of known functions and structures are omitted in the embodiments.
[0040] It should be understood that the phrase "an embodiment" or "this embodiment" throughout the specification means that a specific feature, structure, or characteristic related to the embodiment is included in at least one embodiment of this application. Therefore, "an embodiment" or "this embodiment" appearing throughout the specification does not necessarily refer to the same embodiment. Furthermore, these specific features, structures, or characteristics can be combined in any suitable manner in one or more embodiments.
[0041] Furthermore, reference numerals and / or letters may be repeated in different examples within this application. Such repetition is for the purpose of simplification and clarity and does not in itself indicate a relationship between the various embodiments and / or settings discussed.
[0042] In this article, the term "and / or" is merely a description of the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can mean: A exists alone, B exists alone, and A and B exist simultaneously. The term " / and" in this article describes another type of relationship between related objects, indicating that two relationships can exist. For example, A / and B can mean: A exists alone, and A and B exist alone. In addition, the character " / " in this article generally indicates that the related objects before and after it are in an "or" relationship.
[0043] In this article, the term "at least one" is merely a description of the relationship between related objects, indicating that there can be three relationships. For example, "at least one of A and B" can mean: A exists alone, A and B exist simultaneously, or B exists alone.
[0044] It should also be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion.
[0045] Example 1
[0046] This embodiment mainly introduces a bacterial antimicrobial susceptibility microfluidic chip, including a microbial identification reagent tray 1;
[0047] The microbial identification reagent tray 1 is provided with a shaft hole 2 and a bacterial solution sample loading groove 3;
[0048] The microbial identification reagent tray 1 is equipped with a microchannel 4, a bacterial liquid guiding channel 5, and a bacterial drug sensitivity testing chamber 6.
[0049] The shaft hole 2 is located at the center of the microbial identification reagent tray 1;
[0050] The bacterial solution addition groove 3 is located on the outside of the shaft hole 2;
[0051] The bacterial solution guide channel 5 is located between the bacterial solution sample loading tank 3 and the bacterial drug susceptibility testing chamber 6, and the bacterial drug susceptibility testing chamber 6 is located on the outermost side of the microbial identification reagent tray 1.
[0052] The bacterial solution sample loading tank 3, the bacterial solution guide channel 5, and the bacterial drug sensitivity testing chamber 6 are connected by a microchannel 4. Please refer to the following for the specific design: Figure 1 and Figure 2 .
[0053] Furthermore, the microbial identification reagent tray 1 is also provided with a vent hole 7, which is connected to the bacterial liquid guide channel 5 through the microfluidic channel 4.
[0054] Furthermore, the bacterial drug sensitivity testing chamber 6 is evenly distributed on the outside of the bacterial solution guide channel 5 and is connected to the bacterial solution guide channel 5 through the microchannel 4.
[0055] Furthermore, the different bacterial susceptibility testing chambers 6 are equipped with dried substrates of different concentration gradients of antibiotics.
[0056] Furthermore, the volume of each bacterial susceptibility testing chamber 6 is 25 μL.
[0057] Furthermore, the microchannel 4 is an S-shaped microfluidic channel.
[0058] Furthermore, the bacterial solution sample loading tank 3 has a semi-circular arc-shaped structure.
[0059] Furthermore, the tail end of the bacterial solution sample addition tank 3 is connected to the bacterial solution guide channel 5 through the microchannel 4.
[0060] Furthermore, a dynamic balancing groove 8 is provided at the position corresponding to the shaft hole 2 in the bacterial solution sample addition groove 3.
[0061] Current microplate methods for microbial antimicrobial susceptibility testing require 100–200 μL of bacterial suspension per well. If 40 wells are used for identification, at least 4–8 ml of bacterial suspension is needed. However, the bacterial antimicrobial susceptibility testing microfluidic chip designed in this application has a volume of only 25 μL per chamber. Using 40 chambers, only about 2 ml of bacterial suspension is required. This reduction in bacterial suspension means a smaller number of bacteria are needed to prepare a bacterial suspension of a certain concentration. The former method typically requires culturing on solid plates and then picking colonies for further amplification to obtain a sufficient number of bacteria. The latter method only requires picking 2–5 colonies directly to meet the identification needs, thus significantly reducing the amplification process and time.
[0062] Current microbial susceptibility testing methods, such as microplate strips or E-test strips, can only perform one antibiotic susceptibility test at a time. When multiple antibiotic MIC concentration gradients need to be measured, the process is cumbersome, time-consuming, and labor-intensive. However, the bacterial susceptibility microfluidic chip designed in this application can integrate several antibiotics, each with several concentration gradients. This allows for the time-saving and labor-saving completion of multiple antibiotic MIC tests required in clinical practice at once, such as MIC detection chips for ceftazidime / avibactam, polymyxin, tigecycline, etc. Based on the CRE enzyme production results and the MIC of key drugs, timely adjustments to treatment plans and implementation of effective infection control measures can effectively curb bacterial resistance and its spread.
[0063] Current fully automated microbial identification and susceptibility analyzers for microplate microbial susceptibility testing are complex in structure and bulky due to the cumbersome sample loading process. This necessitates the use of an XYZ robotic arm and a microplate cover gripping device. In contrast, the bacterial susceptibility microfluidic chip designed in this application requires only a centrifugation module, replacing the complex XYZ robotic arm and microplate cover gripping device. This simplifies the design, reduces equipment costs, and minimizes the likelihood of mechanical failure.
[0064] Because the identification of structural microorganisms requires a long time, generally 4 to 24 hours, delaying the evaporation of the bacterial culture medium is a crucial issue that must be addressed during this extended incubation period. Current microplate methods for microbial drug sensitivity testing use unsealed covers, resulting in significant liquid evaporation during incubation and impacting the accuracy of the results. The bacterial drug sensitivity microfluidic chip designed in this application employs a film-sealed design, greatly reducing culture medium evaporation. Furthermore, a tortuous S-shaped microfluidic channel is designed at the microchannel outlet to further delay evaporation. Experimental data show that without the tortuous S-shaped microfluidic channel, after 16 hours of incubation at 37°C, the liquid evaporation is approximately 5%; with the tortuous S-shaped microfluidic channel, after 16 hours of incubation at 37°C, it is less than 1%, while the conventional capped microplate method results in evaporation exceeding 30%.
[0065] Example 2
[0066] Based on the above embodiment 1, this embodiment mainly introduces a method for using a bacterial drug sensitivity microfluidic chip, including the following steps:
[0067] Step S1: Add a sample solution of a certain concentration of the bacterial solution to be tested into the bacterial solution addition tank 3;
[0068] Step S2: Under the action of centrifugal force, the bacterial solution flows through the microchannel 4 to the bacterial solution guide channel 5, and then fills each bacterial drug sensitivity testing chamber 6 through the microchannel 4.
[0069] Step S3: Place the microfluidic chip in a bacterial incubator and incubate for a certain period of time, then remove it.
[0070] Step S4: Place the sample into a microfluidic chip detector. The microfluidic chip detector performs photomicrography on each bacterial drug susceptibility testing chamber 6. Based on the color or turbidity changes in the photographic images before and after culture, determine whether bacteria have grown. Combined with the type and concentration of antibiotics in each bacterial drug susceptibility testing chamber 6, the final drug susceptibility analysis results are given.
[0071] Current microplate methods for bacterial suspension testing require adding the bacterial suspension to each well using a pipette. Since antibiotic susceptibility testing involves approximately 40 wells, this process is cumbersome and inefficient. The complexity also increases the risk of aerosols and cross-contamination, and introduces some loading error. This application utilizes centrifugation to fill the reaction chamber with the test bacterial suspension in a single centrifugation operation. The loading process is quick, simple, and highly efficient. Since the loading occurs within the microfluidic chip, it eliminates aerosol generation and cross-contamination. The batch-to-batch error of the microfluidic chip reaction chamber volume is less than 0.1%, and the repeatability error is less than 0.1%.
[0072] For drug susceptibility testing of certain microorganisms requiring a harsh eutrophic environment, the current microplate method necessitates a dedicated harsh eutrophic incubator (such as a CO2 incubator or anaerobic incubator). In such an environment, once a test plate needs to be removed for observation, the entire harsh eutrophic environment must be re-established. This process is resource-intensive and complex, significantly limiting the application of clinical drug susceptibility testing for harsh bacteria. For meningococci requiring CO2 culture, this application allows for the establishment of a CO2-intensive microenvironment by adding chemical reagents to the sample loading tank after centrifugation of the bacterial suspension into the bacterial susceptibility testing chamber (using the sodium bicarbonate-hydrochloric acid method: sodium bicarbonate and hydrochloric acid are added to the sample loading chamber in a specific ratio, and the sample loading tank and vent are sealed with a membrane; the reaction of sodium bicarbonate and hydrochloric acid produces carbon dioxide, establishing a CO2 culture environment). For anaerobic bacteria requiring an anaerobic culture environment, after centrifugation of the bacterial suspension into the bacterial susceptibility testing chamber, an appropriate amount of mercaptoethanol or pyrogallol and sodium hydroxide solution is added to the sample loading tank. After sealing the sample loading tank with a membrane, the absorption of oxygen creates an anaerobic culture environment inside the chip. The chip maintains a intensive microenvironment throughout the entire culture and identification reaction cycle, allowing for continuous observation of bacterial susceptibility test results under this intensive microenvironment. Furthermore, the chip can be cultured in the same incubator as conventional culture chips, greatly simplifying the culture environment for both intensive and common microorganisms and conserving resources.
[0073] Example 3
[0074] Based on the above embodiments 1-2, this embodiment mainly focuses on certain microorganisms that require a harsh culturing environment, and introduces a method for using a bacterial antimicrobial susceptibility microfluidic chip designed in this application, including the following steps:
[0075] Step S1: Add a sample solution of a certain concentration of the bacterial solution to be tested into the bacterial solution addition tank 3;
[0076] Step S2: Under the action of centrifugal force, the bacterial solution flows through the microchannel 4 to the bacterial solution guide channel 5, and then fills each bacterial drug sensitivity testing chamber 6 through the microchannel 4.
[0077] Step S3: Add chemical reagents to the bacterial solution loading tank 3 to create a fastidious microenvironment, and seal the bacterial solution loading tank 3 and the vent 7 with a membrane.
[0078] Step S4: Place the microfluidic chip in a bacterial incubator and incubate for a certain period of time, then remove it.
[0079] Step S5: Place the sample into the microfluidic chip detector. The microfluidic chip detector performs photomicrography on each bacterial drug susceptibility testing chamber 6. Based on the color or turbidity changes in the photographic images before and after culture, determine whether bacteria have grown. Combined with the type and concentration of antibiotics in each bacterial drug susceptibility testing chamber 6, the final drug susceptibility analysis results are given.
[0080] For certain microorganisms that require a harsh environment for cultivation, after the bacterial suspension is centrifuged and enters the bacterial drug susceptibility testing chamber, chemical reagents can be added to the bacterial suspension loading tank to create a harsh microenvironment. For example, the CO2 culture environment uses the sodium bicarbonate-hydrochloric acid method: sodium bicarbonate and hydrochloric acid are added to the bacterial suspension loading tank in a certain proportion, and the bacterial suspension loading tank and vent are sealed with a membrane. The contact between sodium bicarbonate and hydrochloric acid produces carbon dioxide, thus creating a CO2 culture environment. The anaerobic culture environment uses an appropriate amount of mercaptoethanol or pyrogallol and sodium hydroxide solution. After sealing the bacterial suspension loading tank and vent with a membrane, the absorption of oxygen creates an anaerobic culture environment inside the chip.
[0081] The above description is merely a preferred embodiment of the present invention and does not limit the scope of protection of the present invention. For those skilled in the art, the present invention can have various modifications and variations. Any changes, modifications, substitutions, integrations, and parameter alterations to these embodiments within the spirit and principles of the present invention, achieved through conventional substitutions or by achieving the same function without departing from the principles and spirit of the present invention, fall within the scope of protection of the present invention.
Claims
1. A bacterial antimicrobial susceptibility microfluidic chip, characterized in that, Includes a microbial identification reagent tray (1); The microbial identification reagent tray (1) is provided with a shaft hole (2) and a bacterial solution dispensing groove (3); The microbial identification reagent tray (1) is provided with a microchannel (4), a bacterial liquid guiding channel (5), and a bacterial drug sensitivity testing chamber (6); The shaft hole (2) is located at the center of the microbial identification reagent tray (1); The bacterial solution loading groove (3) is located outside the shaft hole (2), and the bacterial solution loading groove (3) has a semi-circular arc structure; The bacterial solution guide channel (5) is located between the bacterial solution sample loading tank (3) and the bacterial drug susceptibility testing chamber (6), and the bacterial drug susceptibility testing chamber (6) is located on the outermost side of the microbial identification reagent tray (1); The bacterial solution sample loading tank (3), the bacterial solution guiding channel (5), and the bacterial drug sensitivity testing chamber (6) are connected by a microchannel (4), which is an S-shaped microfluidic channel; The microbial identification reagent tray (1) is also provided with a vent (7), which is connected to the bacterial liquid guide channel (5) through a microchannel (4); The bacterial drug susceptibility testing chamber (6) is evenly distributed on the outside of the bacterial liquid guiding channel (5) and is connected to the bacterial liquid guiding channel (5) through the microchannel (4); Different bacterial susceptibility testing chambers (6) are equipped with dried substrates of different concentration gradients of antibiotics; The volume of the bacterial susceptibility testing chamber (6) is 25 μl; The tail end of the bacterial solution sample addition tank (3) is connected to the bacterial solution guide channel (5) through the microfluidic channel (4); The bacterial sample addition groove (3) is also provided with a dynamic balancing groove (8) at the position corresponding to the shaft hole (2).
2. The method of using a bacterial antimicrobial susceptibility microfluidic chip according to claim 1, characterized in that, Includes the following steps: Step S1: Add a sample solution of a certain concentration of the bacterial solution to be tested into the bacterial solution addition tank (3); Step S2: Under the action of centrifugal force, the bacterial solution flows through the microchannel (4) to the bacterial solution guide channel (5), and then through the microchannel (4) to fill each bacterial drug sensitivity test chamber (6); Step S3: Place the microfluidic chip in a bacterial incubator and incubate for a certain period of time, then remove it. Step S4: Place the sample into the microfluidic chip detector. The microfluidic chip detector performs microscopic photography on each bacterial drug susceptibility testing chamber (6). Based on the color or turbidity changes of the photographic images before and after culture, determine whether bacteria have grown. Combine the types and concentrations of antibiotics in each bacterial drug susceptibility testing chamber (6) to finally give the drug susceptibility analysis results.
3. The method of using a bacterial antimicrobial susceptibility microfluidic chip according to claim 2, characterized in that, In step S3, for certain microorganisms that require a harsh environment for cultivation, after the bacterial culture is centrifuged and enters the bacterial drug sensitivity testing chamber (6), chemical reagents are added to the bacterial culture sample loading tank (3) to create a harsh microenvironment, and the bacterial culture sample loading tank (3) and the vent (7) are sealed with a membrane.